Incyte周二公布的年度销售额预期低于华尔街预估，其主要增长动力Opzelura药物预计表现不佳，这加 剧了外界对这家制药商能否抵消其最畅销药物Jakafi即将到来的专利到期影响的担忧。 这家总部位于特拉华州威尔明顿的公司，股价在盘前交易中下跌超过4%。 公司预计Opzelura在2026年实现营收7.5亿至7.9亿美元，低于分析师预估的8.015亿美元。 尽管第四季度表现强劲——Opzelura销售额大涨28%至2.073亿美元，高于预期的1.956亿美元——但公司 仍给出了谨慎展望。 蒙特利尔银行（BMO）分析师Evan Seigerman表示："Opzelura的预期偏弱，意味着2026年仍有不少工作 要做。"投资者正密切关注，在Jakafi专利到期后，这款增长型药物能否填补收入缺口。 Opzelura用于治疗12岁及以上患者的白癜风和特应性皮炎。公司预计今年下半年将获得监管审批结果， 计划2026年底在美国以外市场推出其中重度特应性皮炎适应症。 Jakafi是Incyte用于治疗骨髓纤维化、真性红细胞增多症等血液癌症的旗舰药物，目前仍是公司最畅销产 品。Incyte预计2026年Jakafi销售额为 ...

Core Insights - Novartis has initiated a wave of acquisitions this year, with a focus on enhancing its drug pipeline and compensating for revenue declines from key therapies due to patent expirations [1][2] - The company reported a 6% increase in operating profit, reaching $5.46 billion in Q3, slightly above analyst expectations of $5.4 billion [1] - Q3 revenue was $13.91 billion, representing an 8.4% year-over-year growth, exceeding forecasts, while adjusted EPS was $2.25, falling short of expectations by $0.06 [1] Financial Performance - Novartis' Q3 operating profit adjusted for special items increased to $5.46 billion, surpassing analyst expectations [1] - The company has raised its annual performance outlook twice this year, maintaining its 2025 financial guidance with projected sales growth in the "mid-high single digits" and adjusted operating profit growth in the "low double digits" [1] Product Performance - The heart drug Entresto, which lost patent protection this year, generated $1.88 billion in sales during Q3, with total sales expected to reach $7.82 billion globally in 2024 [1] - Analysts had anticipated Q3 sales for Entresto to be $1.77 billion [1] - The psoriasis treatment drug Cosentyx faced competition from AbbVie's Bimzelx, with sales remaining flat at $1.7 billion year-over-year [2] - The breast cancer drug Kisqali, launched last year, achieved sales of $1.33 billion [2] Acquisition Strategy - Novartis is actively pursuing acquisitions and licensing deals valued at $30 billion, including a $12 billion acquisition of U.S. biotech company Avidity [1]